You are here:

Forthcoming Submission: regorafenib (Stivarga)

Indication: As a monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Drug Details

Drug Name: regorafenib (Stivarga)
Drug Manufacturer: Bayer Plc
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/02/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back